CNBC February 20, 2025
Key Points
– Eli Lilly Chief Scientific Officer Dan Skovronsky said newer obesity medicines need to deliver more than just weight loss to compete with Zepbound and Wegovy.
– The development of pills and more potent drugs are two areas where Lilly is focusing.
– Skovronsky said he is most excited about treating more health conditions with GLP-1s and other incretin medicines.
Dan Skovronsky knows what makes a good obesity drug.
As chief scientific officer at Eli Lilly, he’s already done it once with the company’s weekly shot, Zepbound. He’s trying to do it again with a more convenient daily pill, then repeat the feat with a shot that could be even more powerful than Zepbound. And that’s not counting...
Today's Sponsors
Today's Sponsor